If you typed Vera Research into a search box, you’re probably building a shortlist for a trial in New Zealand. This article uses only what Vera publishes (veraresearch.nz, What we do) and compares it with bioaccess®, the First-in-Human CRO for medical devices in Latin America since 2010. It’s a practitioner comparison, not a teardown.
What Vera publishes
Vera Research focuses on vascular devices, therapies and endovascular procedures. It says it has “deep experience in first-in-human trials, preclinical requirements, and regulatory approvals”, and offers early-stage consulting, study design, regulatory approvals, patient recruitment and on-the-ground trial management. It describes itself as “combining global insights with expertise in New Zealand”. Its public site doesn’t list named studies, headcount or certifications.
Vera vs bioaccess®
| Dimension | Vera | bioaccess® |
|---|---|---|
| Core focus | Vascular and endovascular first-in-human consulting and trial management | First-in-human and early feasibility studies for medical devices, across therapeutic areas |
| Geography | New Zealand | Latin America, since 2010 |
| Device FIH track record | Stated focus; no named studies on its public site | Published case studies on bioaccessla.com |
| After the trial | See provider site | Multi-country sanitary registration and in-country holder service |
Where each one fits
If you have a vascular or endovascular device and want a New Zealand team that specialises in that field, Vera is a natural shortlist entry.
If the job is a first-in-human or early feasibility study for a medical device, and especially one that needs more patients than one small country can supply, bioaccess® was built for exactly that. It has run device studies in Latin America since 2010. When the study ends, the same company can register and hold the device across the region through its market access service. Ask any CRO on your list, including Vera, for a named or de-identified device first-in-human study: device class, implant or not, number of patients, ISO 14155 monitoring plan, and how the data was used in an FDA file.
New Zealand offers real country advantages:
– device trials need HDEC ethics approval but no Medsafe approval;
– one ethics review covers all sites;
– HDEC aims to decide within 15 days (expedited review) or 35 days (full review).
Those advantages belong to the country, not to Vera. New Zealand also has about 5.36 million people, and commercial sponsors must provide ACC-equivalent injury compensation. We set out the country comparison in New Zealand vs Latin America for first-in-human device trials and bioaccess® vs New Zealand.
Frequently asked questions
Is Vera Research a full-service CRO?
Its site describes consulting, study design, regulatory approvals, recruitment and on-the-ground trial management for vascular research. Ask Vera which functions it provides directly, such as monitoring, data management and safety.
Does a device trial in New Zealand need Medsafe approval?
No. Under the Medicines Act 1981 there is no provision to require approval of device trials. Medsafe asks to be notified, and HDEC ethics approval is required (Medsafe guideline, §7).
Can Latin American device data support an FDA submission?
Yes. Foreign device data is eligible for FDA review under 21 CFR 812.28 when GCP, independent ethics review and informed consent are met, and FDA can validate the data. Eligibility isn’t clearance or approval.
When is bioaccess® the better choice than Vera?
When the study is a device first-in-human or early feasibility study, needs a second country or more patients, or needs U.S.-adjacent time zones and a route to registration in Latin America.
Ready to compare a proposal? Request a first-in-human study proposal.
Competitor facts come from the Vera public pages linked above, reviewed 28 October 2026 for bioaccess® competitive research. The claims are theirs. No sponsors, prices or contacts are invented.